Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection.

  title={Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection.},
  author={John F. Morlese and Chloe Orkin and Riaz Abbas and Catherine T Burton and Nadeem A Qazi and Mark R. Nelson and Nesrina Imami and Brian George Gazzard},
  volume={17 9},
Immunological Profile of HIV-Infected Patients with Tuberculosis Associated-Immune Reconstitution Inflammatory Syndrome: A Systematic Review
The results indicated that TB-IRIS was associated with the recovery of Mtb-specific immune response, demonstrated by an increased frequency of specific IFN-g-producing cells and specific multifunctional T-lymphocytes. Expand
Classical complement and inflammasome activation converge in CD14highCD16- monocytes in HIV associated TB-immune reconstitution inflammatory syndrome
Primary blood mononuclear cells from patients were more sensitive to ex-vivo complement-mediated IL-1β secretion than healthy control cells in a NLRP3-dependent manner and targeting this pathway may represent a novel therapeutic approach for IRIS or related inflammatory syndromes. Expand
Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease
The current understanding of the immunopathogenesis, the presentation of TB-IRIS and the evidence for management recommendations are summarized, with a focus on management strategies in the highly morbid central nervous system (CNS) form of the disease. Expand
British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019
The overall purpose of these guidelines is to help physicians manage adults with tuberculosis (TB)/human immunodeficiency virus (HIV) co‐infection. Recommendations for the treatment of TB inExpand
Thalidomide in the Treatment of Sweet's Syndrome and Eosinophilic Folliculitis Associated With Immune Reconstitution Inflammatory Syndrome
A rare case of an AIDS patient who developed eosinophilic folliculitis and Sweet's syndrome within 1 month of initial antiretroviral therapy, presumably due to immune reconstitution inflammatory syndrome is reported. Expand
Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)
If results of this trial demonstrate the efficacy and safety of prednisone, this will provide clinicians with an evidence-based preventive strategy in patients at high risk for paradoxical TB-IRIS when initiating ART. Expand
HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome
Patients co-infected with HIV-1 and tuberculosis (TB) are at risk of developing TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) following commencement of antiretroviral therapyExpand
Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report
The results suggest that the production of inflammatory cytokines by unstimulated T-lymphocytes could contribute to occurrence of leishmaniasis associated with IRIS. Expand
Leishmaniasis as a Manifestation of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients
Commonly found characteristics included cutaneous involvement, regardless of Leishmaniasis species; appearance of lesions unrelated to time of probable Leishmania infection; rapid recovery of CD4 count following HAART; and rapid progression. Expand
TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB
A distinct pattern of pre-ART T-cell and cytokine markers appear to poise the immune response of certain patients to develop TB-IRIS, which may contribute to superior immune control of TB/HIV co-infection and better clinical outcome. Expand


Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy.
People who had an HHV-associated IRD had increased plasma bioavailable IL-6 before HAART, compared with patients who experienced a non-HHV- associated IRD and with control patients, and their plasma bioavailability increased progressively over 3-4 years of treatment. Expand
Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART.
Measurement of pathogen-specific immune responses may help in the diagnosis of immune restoration diseases and the next step may be to continue HAART and therapy for the related infection and add anti-inflammatory drugs, such as corticosteroids. Expand
Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.
The failure of HIV-1 plasma load to decline significantly during the initial months of anti-tuberculosis treatment is associated with high, sustained systemic levels of TNF-alpha, which may represent dysregulation of cytokine production in these African patients. Expand
Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy
A patient with HIV infection was successfully treated for pulmonary tuberculosis, but pulmonary inflammation and lymphadenitis worsened dramatically after subsequent combination antiretroviral therapy, probably caused by restoration of pathogen‐specific cellular immunity. Expand